ArticleNature chemical biology2016
Compounds that select against the tetracycline-resistance efflux pump.
Article in Nature chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Synergistic effect of the hybrid compounds of cationic pillararene and an efflux pump inhibitor against Gram-negative bacteria.RSC medicinal chemistry · 2025Article
- Harnessing the effect of iron deprivation to attenuate the growth of opportunistic pathogenAntimicrobial agents and chemotherapy · 2025Article
- Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.Scientific reports · 2025Article
- The tetracycline resistome is shaped by selection for specific resistance mechanisms by each antibiotic generation.Nature communications · 2025Article
- Guanethidine Restores Tetracycline Sensitivity in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Drug combinations targeting antibiotic resistance.npj antimicrobials and resistance · 2024Review
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.Metabolites · 2023Review
- Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance.Nature communications · 2023Article
- Review
- Antimicrobial resistance: new insights and therapeutic implications.Applied microbiology and biotechnology · 2022Review
- Article
- Expanding the search for small-molecule antibacterials by multidimensional profiling.Nature chemical biology · 2022Review
- Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse.Scientific reports · 2022Article
- Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections.Nature communications · 2022Article
- Modular and Single-Cell Sensors of Bacterial Ser/Thr Kinase Activity.ACS synthetic biology · 2021Article
- Ubiquitous selection for mecA in community-associated MRSA across diverse chemical environments.Nature communications · 2020Article
- Bacterial variability in the mammalian gut captured by a single-cell synthetic oscillator.Nature communications · 2019Article
- Transient antibiotic resistance calls for attention.Nature microbiology · 2019Article
- Crossroads of Antibiotic Resistance and Biosynthesis.Journal of molecular biology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 3 countries.
Funding
Abstract
We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline-resistance efflux pump in Escherichia coli and identified two hits, β-thujaplicin and disulfiram. Treating a tetracycline-resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.